A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

J Bae1,2, R Prabhala1,2,3, A Voskertchian4, A Brown1,2, C Maguire5, P Richardson1,2, G Dranoff1,2, KC Anderson1,2 and NC Munshi1,2,3

We evaluated a cocktail of HLA-A2-specific peptides including heteroclitic XBP1 US184–192 (YISPWILAV), heteroclitic XBP1 SP367–375 (YLFPQLISV), native CD138260–268 (GLVGLFAV) and native CS1259–247 (SLFVLGLFL), for their ability to elicit multipeptide-specific cytotoxic T lymphocytes (MP-CTLs) using T cells from smoldering multiple myeloma (SMM) patients. Our results demonstrate that MP-CTLs generated from SMM patients’ T cells show effective anti-MM responses including CD137 (4-1BB) upregulation, CTL proliferation, interferon-γ production and degranulation (CD107a) in an HLA-A2-restricted and peptide-specific manner. Phenotypically, we observed increased total CD3+CD8+ T cells (>80%) and cellular activation (CD69+) within the memory SMM MP-CTL (CD45RO−/CD3+CD8+) subset after repeated multipeptide stimulation. Importantly, SMM patients could be categorized into distinct groups by their level of MP-CTL expansion and antitumor activity. In high responders, the effector memory (CCR7−CD45RO−/CD3+CD8+) T-cell subset was enriched, whereas the remaining responders’ CTL contained a higher frequency of the terminal effector (CCR7−CD45RO−/CD3+CD8+) subset. These results suggest that this multipeptide cocktail has the potential to induce effective and durable memory MP-CTL in SMM patients. Therefore, our findings provide the rationale for clinical evaluation of a therapeutic vaccine to prevent or delay progression of SMM to active disease.

Leukemia advance online publication, 17 June 2014; doi:10.1038/leu.2014.159

KEY POINTS

- The multipeptide induces anti-myeloma-specific T lymphocytes targeting XBP1, CD138 and CS1 antigens from smoldering myeloma patients.
- Multipeptide cocktail has an immunotherapeutic potential as a vaccine in smoldering myeloma patients to control the disease progression.

INTRODUCTION

Smoldering myeloma (SMM) is a precursor to multiple myeloma (MM) in which the patient does not display any of the typical myeloma-related symptoms, such as elevated calcium levels, kidney damage, anemia or bone lesions.1,2 Early treatment strategies for SMM are particularly attractive, as the rate of progression to MM is substantially greater (10%) as compared with asymptomatic precursor states is associated with worsening immune dysfunction. Defects in T-cell function, including loss of tumor-specific effector T-cell activity and induction of Treg cells, along with cytokines and growth factors, including interleukin-6 (IL-6), macrophage inflammatory protein-1α, insulin-like growth factor-I, vascular endothelial growth factor and hepatocyte growth factor, contribute to myeloma pathogenesis.9,10 The expression of PD-L1, which is detected on MM cells but not in healthy donors, may also be associated with reduced susceptibility to tumor cell lysis by cytotoxic T lymphocyte (CTL).11,12 MM has the unique ability to elude immunosurveillance through various mechanisms including reduced T-cell cytotoxic activity, induction of dendritic cell dysfunction, expansion of myeloid-derived suppressor cells, decreased responsiveness to IL-2 and defects in B-cell immunity.13–15 These immune defects associated with MM pathogenesis account at least in part, for the failure of recent immunotherapy trials in patients with MM.16 Thus, we hypothesize that early immunotherapeutic intervention in SMM patients with retained immune function may offer an opportunity to prevent or delay disease progression to active MM.

Antigen-specific cancer vaccines targeting various tumor-associated antigens have been shown to elicit tumor-suppressive responses in the clinical setting. A large number of clinical trials have been carried out using different tumor-associated antigen with minimal toxicities and side effects.17,18 XBP1 (X-box-binding protein 1), CD138 ( Syndecan-1) and CS1 (CD2 subset 1, CRACC,
SLAMF7, CD319) antigens are highly expressed on MM with therapeutic potential, as demonstrated in preclinical and clinical studies.19–24 In previous studies, we identified immunogenic HLA-A2-specific peptides derived from each of these target antigens, including heterotic XBP1 unspliced (US),184–192 (YSPWILAV),25 heterotic XBP1 spliced (SP),367–375 (YLFQQLSV),25 native CD138,260–268 (GLVGLIFAV)26 and native CS1,239–247 (SLFVLGLFL)27 peptides. These selected immunogenic peptides, either individually or combined as a four-peptide cocktail, induced antigen-specific CTL with functional activities against HLA-A2 + MM cells.21,22,25 Expanding on our previous studies, we demonstrate here that these HLA-A2-specific XBP1 US, XBP1 SP, CD138 and CS1 peptides are highly immunogenic to SMM patients’ T cells and induce highly effective anti-MM immunity. The capacity for SMM patients’ T cells to respond to each of these peptides and trigger expansion of CD3 + CD8 + CTL with functional activities against the respective epitopes on MM cells provides the framework for clinical evaluation of vaccination with these peptides in patients with SMM to prevent progression to active disease.

MATERIALS AND METHODS

Cell lines

MM cell lines, including HLA-A2 + McCAR, HLA-A2 + U266, HLA-A2 + MM1S and HLA-A2 + RPMI along with the chronic myelogenous leukemia K562 cell line, were obtained from the American Type Culture Collection. The K562 cell line transduced with HLA-A*0201 cDNA (K562-A*0201) was provided by Dr P Cresswell (Yale University). The T2 cell line, a human B- and T-cell hybrid-expressing HLA-A2 molecules, was provided by Dr J Mollendr (University of Texas MD Anderson Cancer Center). All cell lines were cultured in RPMI-1640 medium (Gibco-Life Technologies, Walkersville, MD, USA), 100 IU/ml penicillin and 100 μg/ml streptomycin (Gibco-Life Technologies).

Synthetic peptides

Heterotic XBP1 US,184–192 (YSPWILAV), heterotic XBP1 SP,367–375 (YLFQQLSV), native CD138,260–268 (GLVGLIFAV) and native CS1,239–247 (SLFVLGLFL) peptides, were synthesized by standard 9-fluorenylmethyl-oxycarbonyl chemistry, purified to >90% using reverse-phase chromatography, and validated by mass-spectrometry for molecular weight (Biosynthesis, Lewisville, TX, USA). These peptides were used as antigen-presenting cells (APCs),25,28 to stimulate autologous CD3 + T cells (>99% purity) to generate multipeptide-specific cytotoxic T lymphocytes (MP-CTLs).

Induction of MP-CTLs from SMM patients’ T lymphocytes

MP-CTLs were generated ex vivo by repeated stimulation of CD3 + T lymphocytes obtained from HLA-A2 + SMM patients with a cocktail of heterotic XBP1 US,184–192 (YSPWILAV), heterotic XBP1 SP,367–375 (YLFQQLSV), native CD138,260–268 (GLVGLIFAV) and native CS1,239–247 (SLFVLGLFL) peptides. In brief, APCs (autologous mature dendritic cell, T2 cells) pulsed overnight with a cocktail containing the four peptides (25 μg/ml total; 6.25 μg/ml peptide) were irradiated at 20 Gy and then used to stimulate autologous CD3 + T cells at a 1:20 APCs-to-CD3 + T-cell ratio in AIM-V medium supplemented with 10% human AB serum. T-cell cultures were re-stimulated every 7 days with irradiated APCs pulsed with the multipeptide cocktail. IL-2 (50 U/ml) was added to the cultures 2 days after the second stimulation, and was replenished weekly until the cultures were completed.

Phenotypic analysis of SMM MP-CTLs

One week after the last stimulation, MP-CTLs and control T cells were harvested, washed in fluorescence-activated cell sorting buffer, and incubated with fluorochrome-conjugated anti-human monoclonal antibodies (mAbs; BD Biosciences, San Diego, CA, USA). After staining, the cells were washed, fixed in 2% paraformaldehyde-PBS and analyzed by flow cytometry.

Table 1. Clinical characteristics of eight SMM patients evaluated

<table>
<thead>
<tr>
<th>ID</th>
<th>Gender</th>
<th>Age (years)</th>
<th>HLA-A2</th>
<th>Treatment</th>
<th>Diagnosis</th>
<th>Cytogenetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>56</td>
<td>Positive</td>
<td>Zoledronic acid, IPH2101, MLN9708, Lenalidomide, dexamethasone</td>
<td>IgG, SMM</td>
<td>Trisomy 7, 9, 11 and 15</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>60</td>
<td>Positive</td>
<td>IPH2101</td>
<td>IgG, SMM</td>
<td>Deletion 17p, translocation (4:14)</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>80</td>
<td>Positive</td>
<td>Zoledronic acid, IPH2101</td>
<td>IgG, SMM</td>
<td>Unknown</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>72</td>
<td>Positive</td>
<td>Zoledronic acid, lenalidomide/placebo, hepatitis B vaccine, IPH2101</td>
<td>IgG, SMM</td>
<td>13q Deletion, IGH/c-MAF fusion, translocation (14;16)</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>55</td>
<td>Positive</td>
<td>Zoledronic acid, elotuzumab</td>
<td>IgG, SMM</td>
<td>Monosomy 13</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>71</td>
<td>Positive</td>
<td>Zoledronic acid, elotuzumab</td>
<td>IgA, SMM</td>
<td>No abnormalities</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>67</td>
<td>Positive</td>
<td>Zoledronic acid</td>
<td>IgA, SMM</td>
<td>No abnormalities</td>
</tr>
<tr>
<td>8</td>
<td>Male</td>
<td>43</td>
<td>Positive</td>
<td>BHQ880A</td>
<td>IgK, Light chain SMM</td>
<td>No abnormalities</td>
</tr>
</tbody>
</table>

Abbreviation: SMM, smoldering multiple myeloma.
SMM MP-CTL degranulation and intracellular interferon (IFN-γ) production in response to MM cells

CD107a degranulation and IFN-γ-producing CD3⁺CD8⁺ T cells were identified within SMM MP-CTL by flow cytometry. Briefly, SMM MP-CTLs were stimulated with HLA-A2⁺ or HLA-A2⁺/C0⁺ MM cell lines, K562 cells, K562-A*0201 cells pulsed with respective peptide or K562-A*0201 cells alone in the presence of CD107a anti-human mAb. SMM MP-CTLs alone served as a negative control. After 1 h incubation, CD28/CD49d mAb (BD, San Diego, CA, USA), as well as protein transport inhibitors Brefeldin A and Monensin (BD), were added for an additional 5 h. Cells were harvested, washed in fluorescence-activated cell sorting buffer and incubated with mAbs specific to CD3, CD8, CCR7, CD45RO, CD69 and/or CD137 antigens.

Figure 1. HLA-A2-restricted cell proliferation of SMM MP-CTLs against MM cells. One week after the fourth stimulation, SMM MP-CTLs (n = 2) were evaluated for cell proliferation in response to various MM cell lines. MP-CTL proliferation is shown as the percent decrease in CFSE expression (P3-gated) on day 5, 6 or 7 of culture. MP-CTL in media alone was used to establish background cell proliferation. MP-CTLs generated from SMM patient #1 (a) or SMM patient #2 (b) showed HLA-A2-restricted cell proliferation on days 5, 6 and 7 in response to HLA-A2⁺ MM cells (McCAR), but not to HLA-A2⁺ MM cells (MM1S, RPMI) or NK-sensitive K562 cells. CFSE, carboxy fluorescein succinimidyl ester.
After surface staining, cells were washed, fixed/permeabilized, stained with anti-IFN-γ mAb (BD), washed with Perm/Wash solution (BD), fixed in 2% paraformaldehyde and analyzed by flow cytometry.

Analysis of SMM MP-CTLs post-lenalidomide treatment
One week after the fourth stimulation, SMM MP-CTLs were harvested and treated with lenalidomide (5 μM, Celgene, Summit, NJ, USA). Following an additional 4 days incubation, MP-CTLs were evaluated for CD107a upregulation and IFN-γ production upon stimulation with MM cells, as described above. In addition, MP-CTLs were evaluated for their phenotype by staining with mAbs specific to CD3, CD8, CD28 and/or CD137 antigens. The cells were washed, fixed in 2% paraformaldehyde and analyzed by flow cytometry.

Statistical analysis
Results are presented as mean ± s.e. Groups were compared using unpaired Student’s t-test. Differences were considered significant when *P<0.05.

RESULTS
A cocktail of HLA-2-specific XBP1 unspliced, XBP1 spliced, CD138 and CS1 peptides was evaluated for its ability to induce antigen-specific CTL from enriched CD3+ T cells of SMM patients (n=4). One week after the first, third and fourth MP-cocktail stimulation, cultures were evaluated for frequency of CD3+CD8+ T cells and CD3+CD4+ T cells by flow cytometry. An increase in the proportion of CD3+CD8+ T cells (Supplementary Figure 1A) and a corresponding decrease in CD3+CD4+ T cells (Supplementary Figure 1B) were detected following each round of multipeptide stimulation. The highest level of CD3+CD8+ (480%) and lowest level of CD3+CD4+ (≤20%) T cells were reached following the fourth stimulation (Figures 1a and b). These results demonstrate that stimulation with XBP1 US/XBP1

---

Figure 2. HLA-A2-restricted IFN-γ production by SMM MP-CTLs against MM cells. One week after the fourth stimulation, SMM MP-CTLs were analyzed for IFN-γ production upon stimulation with various MM cell lines. Representative flow cytometric analysis demonstrates increased IFN-γ production by SMM MP-CTLs in response to HLA-A2+ MM cells (McCARI), but not HLA-A2+ MM cells (MM1S, RPMI) or NK-sensitive K562 cells (a). MP-CTL generated from additional HLA-A2+ SMM patients (n=4) confirmed HLA-A2-restricted IFN-γ production to MM cells, but not to NK-sensitive K562 cells (b).
SP/CD138/CS1 multipeptide induces and expands CD3^+CD8^+ CTL from T cells of SMM patients. Cell proliferation was measured, 1 week after the fourth peptides stimulation, by the decrease in fluorescence intensity (P3 gate) of carboxy fluorescein succinimidyl ester-labeled cells upon incubation with tumor cells. MP-CTL generated from SMM patient #1 (Figure 1a) showed increased CD3^+CD8^+ T-cell proliferation on days 5 (13.6%), 6 (46.2%) and 7 (80.7%) in response to HLA-A2^+ MM cells (McCAR). Similarly, MP-CTLs from SMM patient #2 (Figure 1b) showed increased cell proliferation, starting on day 5 (30.6%) and peaking at day 7 (75.6%) in response to McCAR cells. However, the SMM MP-CTLs did not proliferate to HLA-A2^- MM cells (MM1S, RPMI) or NK-sensitive K562 cells (Figures 1a and b), thereby demonstrating HLA-A2-restricted cell proliferation.

Multipeptide CTLs generated from SMM patients demonstrate HLA-A2-restricted IFN-γ production and CD107a degranulation in response to MM cell lines. We further analyzed SMM MP-CTLs for their functional anti-MM activities, including IFN-γ production and CD107a degranulation, following incubation with various MM cell lines or K562 cells. Representative flow cytometric analyses demonstrate that SMM MP-CTLs had specific IFN-γ production (Figure 2a) against HLA-A2^+ MM cells (McCAR), but not against HLA-A2^- MM cells (MM1S, RPMI) or K562 cells. These observations were confirmed in further analyses of MP-CTL generated from additional HLA-A2^+ SMM patients (n = 4), which displayed IFN-γ production (Figure 2b) in an HLA-A2-restricted manner, and were not mediated by NK cells.

Next, further flow cytometric analyses demonstrate that the SMM MP-CTLs had specific CD107a upregulation (Figure 3a) against HLA-A2^+ MM cells (McCAR, U266), but not against HLA-A2^- MM cells (MM1S, RPMI) or K562 cells. The MP-CTLs generated from other HLA-A2^+ SMM patients (n = 4) displayed the same pattern of response in CD107a degranulation (Figure 3b) as in an HLA-A2-restricted manner without NK cell activity. Interestingly, we detected higher levels of these antitumor activities against HLA-A2^+ MM cell line by MP-CTLs generated from SMM patients #2 and #4 as compared with SMM patients #1 and #3 (Figures 2b and 3b).

Multipeptide CTLs from SMM ‘high’ responders are distinct in phenotype and functional activities against MM cells. SMM MP-CTL (n = 8) were evaluated for total CD3^+CD8^+ T cells, naïve:memory phenotypes and immune function. Results

---

**Figure 3.** HLA-A2-restricted CD107a degranulation by SMM MP-CTLs against MM cells. One week after the fourth stimulation, SMM MP-CTLs were analyzed for CD107a degranulation upon stimulation with various MM cell lines. Representative flow cytometric analysis demonstrates increased CD107a degranulation by SMM MP-CTL in response to HLA-A2^+ MM cells (McCAR, U266), but not HLA-A2^- MM cells (MM1S, RPMI) or NK-sensitive K562 cells (a). MP-CTL generated from additional HLA-A2^- SMM patients (n = 4) confirmed HLA-A2-restricted CD107a degranulation to MM cells, but not to NK-sensitive K562 cells (b).
demonstrate that frequencies of CD3⁺ CD8⁺ T cells in the MP-CTL generated from eight individual SMM patients were similar after four rounds of multipeptide stimulation (Figure 4a). However, total MP-CTL yields were distinctively higher from SMM patients #2 and #4 (1.2–1.3 × 10⁹ cells) as compared with those from the remaining six SMM patients (6–15 × 10⁶ cells). In addition, the
highest level of IFN-γ production and CD107a degranulation in response to target cells (HLA-A2+ U266) was from MP-CTL generated from SMM patients #2 and #4, as compared with those from the other SMM patients (Figure 4a).

Next, we evaluated MP-CTL from the SMM ‘high’ responders (patients #2 and #4) and two SMM ‘normal’ responders (patients #1 and #3) for their naïve/memory phenotypic profile. CD3+ CD8+ T lymphocytes responding to an antigen differentiate from naïve to antigen-specific CTL with various effector and memory functions.22,23 In these studies, SMM MP-CTLs contained main effector memory (EM; CD45RO+CCR7−) and terminal effector (TE; CD45RO−CCR7+) along with a low frequency (<5%) of naïve (CD45RO−CCR7−) and central memory (CD45RO+CCR7+) CD3+ CD8+ T cells (Figure 4b). Importantly, a higher frequency of EM cells was detected in the MP-CTL from ‘high’ responders (SMM #2: 66.4%, SMM #4: 66.5%) as compared with the ‘normal’ responders (SMM #1: 20.5%, SMM #3: 45.3%). In contrast, a higher level of differentiated TE subset was seen in the ‘normal’ responders as compared with the ‘high’ responders.

Based on these observations, we continued to culture the MP-CTL from the ‘high’ responders for 7 weeks with weekly MP-cocktail stimulation. Overall, we observed increased frequency of the EM subset in MP-CTL after seven stimulations (SMM #2: 79.1%, SMM #4: 92.2%), without further differentiation into TE subset (Figure 4c). These results suggest that maintenance of an EM CTL subset might be critical for a long-term antitumor response, and may serve as a valuable biomarker when defining the efficacy of the multipeptide vaccine in future clinical studies.

Multipeptide CTLs generated from SMM patients include a high proportion of EM subset producing IFN-γ and expressing CD107a in response to MM cells with the highest levels detected in MP-CTL from SMM ‘high’ responders.

Next, we investigated the level of specific immune activity within different CD3+ CD8+ T-cell naïve/memory subsets of SMM MP-CTL in response to MM cells. Results (% Total Adjusted) were calculated as the percent contribution of each specific subset to total IFN-γ production or CD107a degranulation. The highest IFN-γ production was detected in the EM subset (67.25 ± 16.68%), followed by TE (20.25 ± 5.11%), central memory (8.25 ± 3.15) and naïve (4.0 ± 1.78) subsets, in response to HLA-A2+ McCAR or U266 MM cells (Figure 5a). A similar pattern of immune activity was observed for CD107a degranulation in the SMM MP-CTL (EM: 69.50 ± 6.36, TE: 21.00 ± 3.54, central memory: 7.50 ± 3.43, naïve: 1.50 ± 1.19) to the HLA-A2+ MM cells (Figure 5b). In addition, the EM subset had a higher level of single response, IFN-γ production and CD107a degranulation, as compared with the TE subset (Figures 5a and b). We also observed that the highest proportion of dual functional cells (IFN-γ+/CD107a−) were from MP-CTLs of a SMM ‘high’ responder (patient #2) as compared with those of ‘normal’ responders (patients #1 and #3; Figure 5c). The dual functional activities were confirmed as HLA-A2 restricted in either EM or TE subsets of SMM MP-CTLs.

Finally, we analyzed the level of MM-specific cellular activation (% CD69+ cells) within the CD3+ CD8+ naïve/memory subsets of SMM MP-CTLs. Cellular activation was higher in the CD45RO+ memory cell subset as compared with the CCR7+ CD45RO+ naïve cell counterpart (Supplementary Figure 2). MM-specific cell activation was detected in response to HLA-A2+ McCAR or U266 MM cells, but not to HLA-A2+ MM15 or RPMI MM cells (Supplementary Figure 3). However, unlike the IFN-γ production and CD107a degranulation, the level of CD69 upregulation could not be used to classify SMM MP-CTLs as ‘high’ or ‘normal’ SMM responders.

MP-CTLs induced from SMM patients demonstrate both IFN-γ production and CD107a degranulation in response to each relevant peptide. SMM MP-CTLs were further examined for their ability to specifically recognize and respond to each relevant peptide contained within the MP-cocktail. In these assays, we analyzed individual peptide-specific responses in the activation-induced CD137+ CD3+ CD8+ T-cell population. A representative flow cytometric analysis demonstrates both IFN-γ production and CD107a degranulation by SMM MP-CTL in response to K562-A2+0201 cells pulsed with the relevant peptide, including heteroclitic XBP1 US184–192 (YISPWILAV), heteroclitic XBP1 SP367–375 (YLFPQSLISV), native CD138 260–268 (GLVGLIFAV) and native CS1 329–347 (SLFVLGLFL) peptide, but not to cells pulsed with an irrelevant HLA-A2-specific MAGE-3271–279 (FLWGPRLAV) peptide or cells alone pulsed with no peptide (Figure 6a). In addition, relevant peptide-specific responses were detected in SMM MP-CTLs (n = 3) for both IFN-γ production and CD107a degranulation (Figure 6b). However, there were differences in the magnitude of IFN-γ production and CD107a degranulation in response to each relevant peptide among the MP-CTLs from different SMM patients. Overall, SMM MP-CTLs (n = 3) displayed the highest level of total IFN-γ production or CD107a degranulation against native CD138 260–268 (GLVGLIFAV) followed by heteroclitic XBP1 US184–192 (YSWILAV), native CS1 329–347 (SLFVLGLFL) and heteroclitic XBP1 SP367–375 (YLFPQSLISV) peptides (data not shown). In summary, SMM MP-CTLs are capable of recognizing each relevant peptide in MP cocktail, and targeting multiple tumor-associated antigens on MM cells.

Lenalidomide increases the expression of CD28 co-stimulatory molecule on SMM MP-CTLs and augments their immune activities in response to MM cells. In these studies, we further investigated whether lenalidomide, an immunomodulatory drug, can increase cell yield, regulate expression of critical T-cell molecules or enhance immune function of SMM MP-CTL against MM cells. Short-term treatment of MP-CTLs with lenalidomide (4 days, 5 μM) did not change the overall percentage of total CD3+ CD8+ T cells as compared with the parent non-lenalidomide-treated SMM MP-CTLs. Lenalidomide treatment of SMM MP-CTLs (n = 4) enhanced their anti-myeloma activities against McCAR (Figure 7a) or U266 (Figure 7b) as shown by the ‘% increase’ in IFN-γ production (9–73% increase to McCAR, 6–173% to U266), CD107a degranulation (10–20% increase to McCAR, 5–95% to U266), CD28 expression (9–20% increase to

Figure 4. Characterization of SMM MP-CTLs reveals a subgroup of SMM ‘high’ responders with increased cell yield and immune functional activities. SMM MP-CTLs (n = 8) were analyzed 1 week after their fourth MP-cocktail stimulation. Total cell yield, % CD3+ CD8+ T cells, % IFN-γ production and % CD107a+ degranulation are shown for all MP-CTL in response to HLA-A2+ U266 MM cells (a). A subgroup of MP-CTLs (n = 2) termed SMM ‘high’ responders (#2, #4) displayed higher levels of total cell yield, % IFN-γ+ cells and % CD107a+ cells than MP-CTL generated from other SMM patients. Representative naïve/memory subset analyses of SMM ‘high’ and ‘normal’ responders are demonstrated (b). The percentage of effector memory (EM) cells was increased in the MP-CTLs from SMM ‘high’ responders, whereas MP-CTLs from SMM ‘normal’ responders contained a higher percentage of terminal effector (TE) cells. The MP-CTLs from SMM ‘high’ responders were cultured for an additional three rounds of weekly MP stimulation (total seven stimulations). Continuous expansion of the EM cell subset was detected within the MP-CTLs from SMM ‘high’ responders (patients #2, #4) without a further differentiation into TE cell subset (c).
Multiepitope cocktail to treat smoldering myeloma  
J Bae et al

McCAR, 3–86% to U266) and CD137 upregulation (7–26% increase to McCAR, 0–91% to U266) as compared with baseline values of non-drug-treated MP-CTLs. Therefore, these results demonstrate that lenalidomide treatment augments immune function of SMM MP-CTLs against MM cells, suggesting its potential role to enhance the CTL efficacy post vaccination.

DISCUSSION

Design of an immunotherapeutic approach to induce broad CTL responses specific to multiple antigens may overcome antigen mutation or deletion by tumor cells or the variation or absence of the appropriate T-cell repertoire in the patient. Targeting multiple epitopes on MM cells using a multipeptide vaccine approach could allow a more robust immune response against tumor cells, as compared with vaccines specific to a single antigen. In these studies, we evaluated a cocktail of four immunogenic HLA-A2-specific peptides, heteroclitic XBP1 US184–192 (YISPWILAV), heteroclitic XBP1 SP367–375 (YLFPQLISV), native CD138260–268 (GLVGLIFAV) and native CS1239–247 (SLFVLGLFL), for its ability to evoke anti-MM immunity in T lymphocytes obtained from HLA-A2+ SMM patients. Consistent with our previous studies using ‘healthy’ HLA-A2+ donors’ cells,21,25–27 MP-CTLs generated from SMM patients’ cells displayed a gradual increase in CD3+ CD8+ T cells upon multipeptide stimulation. In addition, the MP-CTLs were predominantly CD45RO+ memory subset and demonstrated HLA-A2-restricted polyfunctional immune activities against MM cells.

Of potential concern during the development of a multipeptide vaccine is epitope dominance along with competition among the peptides for specific HLA-A2 molecules, which may impair the full spectrum of immune responses against all of the desired antigens. Owing to these concerns, individual peptides were administered upon multipeptide stimulation. In addition, the MP-CTLs were HLA-A2 restricted, and the activities were not mediated by NK cells.

It has been hypothesized by others that self-renewal could be the basis for the continual generation of effector lymphocytes from the memory pool.43,44 Recently, studies have revealed dynamic roles for various transcription factors and other factors in effector and memory T cells. The transcriptional repressor Bcl6, transcriptional regulators Id2 and Id3, Wnt-β-catenin signaling pathway and the metabolic status of T cells (that is, fatty acid metabolism, mitochondrial functions) are known to be important for effector or memory cells generation.45,46 In contrast, high levels of T-bet and Blimp1 favor terminally differentiated effector cells. In addition, sustained Akt activation is reported to evoke a transcriptional program that drives differentiation of effector cells and diminishes CTL’ potential to survive.47,48 The pathways beneficial when used in combination with a therapeutic vaccine. In our studies, short-term exposure of MP-CTLs to lenalidomide enhanced MP-CTL function by increasing CD28 expression, IFN-γ production, CD107a degranulation and CD137 upregulation, which are critical biomarkers to detect antitumor activity of CTL. These ex vivo results, along with others’ reports, support the use of lenalidomide as an effective combination therapy to increase vaccine efficacy in patients with MM.34–36

The efficacy of cancer vaccines requires induction of long-term ‘memory’ CD8+ T cells with antitumor activities, which are critical for continuous control of disease. Optimally, cancer vaccine therapies would induce a ‘memory-like’ CD8+ T-cell population, which can self-renew and respond quickly to tumor antigens, while providing effective and persistent long-term antitumor immunity.37,38 Clinical evidence has shown a correlation between levels of ‘EM’ CD (CD45RO+CCR7-/CD3+CD8+ T) in tumor infiltrating lymphocytes with both the absence of early metastatic invasion and increased overall survival in cancer patients.39–42 In these studies, we generated MP-CTLs having effective anti-MM activities in all HLA-A2+ SMM patients tested (n = 8), thereby validating the immunogenicity of the XBP1 US/XBP1 SP/CD138/CS1 multipeptide and its potential as a vaccine for SMM patients. In addition, we identified a small group (n = 2) of SMM MP-CTLs, we termed as ‘high’ responders, based on their increased levels of cell expansion and immune activities against MM cells. The other ‘normal’ SMM MP-CTLs (n = 6) generated in these studies demonstrated characteristic phenotype and functional activities, as seen in our previous study using normal healthy donors’ cells to generate the MP-CTLs.21 MP-CTLs from SMM ‘high’ responders demonstrated ~100 times greater CD3+ CD8+ T-cell expansion and increased levels of anti-MM immunity as compared with SMM ‘normal’ responders. Importantly, enrichment in EM cell subset was detected in the MP-CTLs from SMM ‘high’ responders, whereas SMM ‘normal’ responders contained a higher proportion of TE subset.

Comparison of antitumor activities revealed that the EM subset mediated greater anti-MM immunity than the counterpart TE subset. Furthermore, EM CTL from SMM ‘high’ responders were continuously maintained and expanded following seven cycles of MP-stimulation, without differentiation into TE CTL. Thus, these observations emphasize the potential to effectively induce strong and extended antitumor immunity upon MP-stimulation by maintaining the ‘EM’ CTL in patients.

Figure 5. Characterization of immune function in the naïve/memory cell subsets of SMM MP-CTLs. (a, b) The specific immune function of SMM MP-CTLs (n = 4) was evaluated within the naïve/memory CD3+CD8+ T-cell subsets in response to MM cells. The proportion (%) of each naïve/memory cell subset contribution to total immune activity is expressed as % Total Adjusted. The highest level of IFN-γ production (a) or CD107a degranulation (b) was detected in the effector memory (EM) cell subset, followed by the terminal effector (TE), central memory (CM) and naïve cell subsets within the SMM MP-CTL in response to HLA-A2+ MM cells. The EM cells from SMM ‘high’ responders’ MP-CTLs demonstrate increased IFN-γ production and CD107a degranulation as compared with those from SMM ‘normal’ responders’ MP-CTLs. (c) SMM MP-CTL (n = 3) stimulated with HLA-A2+ MM cells were analyzed for the % IFN-γ+/CD107a+ double-positive cells within the EM or TE cell subset. EM cells demonstrated a higher level of both IFN-γ production and CD107a degranulation as compared with TE cells. EM cells in MP-CTLs from the SMM ‘high’ responders had the highest % IFN-γ+/CD107a+ cells. The IFN-γ+/CD107a+ responses in the SMM MP-CTLs were HLA-A2 restricted, and the activities were not mediated by NK cells.
and differences in hierarchical differentiation between ‘high’ and ‘normal’ SMM responders to the peptides present a unique challenge to developing optimal vaccine strategies. Our ongoing studies will elucidate the mechanism for arresting differentiation of long-lived and antigen-specific memory CTL to facilitate development of immunotherapeutic strategies.

In summary, we demonstrate in ex vivo that a cocktail of HLA-A2-specific peptides, heteroclitic XBP1 US184–192, heteroclitic XBP1 SP367–375, native CD138260–268 and native CS1239–247 can elicit MP-CTLs with anti-MM immunity from SMM patients’ T cells. These data provide evidence for induction of an effective and durable ‘EM’ MP-CTL with strong antitumor activity in a subset of...
SMM patients ('high' responders). In addition, it would be of interest to know the impact of this MP vaccine in patients with symptomatic MM to see if there any of the known immune regulatory issues limit the clinical efficacy of the vaccine.49,50

Combining adjuvant therapies to enhance immune function in both myeloma and SMM will be explored in our future studies. These results provide the framework for a clinical trial with our multipeptide vaccination strategy targeting XBPI, CD138 and CS1 antigens to delay or prevent progression of SMM to active MM.

CONFLICT OF INTEREST

KC Anderson is an advisory board for Celgene, Millennium, Gilead, Sanofi-Aventis and Onyx. NC Munshi serves on the advisory boards of Celgene, Onyx and Johnson & Johnson, and PG Richardson serves on the advisory boards of Celgene, Millennium and Johnson & Johnson. NC Munshi, KC Anderson and J Bae have ownership interest and are advisory board members in OncoPep Inc. The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We acknowledge the generous gift of K562-A*0201 cells from Dr P Cresswell (Yale University, New Haven, CT, USA). We also thank Mr J Daley and Ms S Lazo-Kallanian from the Flow Cytometry facility at Dana-Farber Cancer Institute for providing flow cytometry assistance. This work was supported in part by grants from the National Institutes of Health Grants RO1-124929 to Dr NC Munshi, PS0-100007, PO1-78378 and PO1155258 to Drs KC Anderson and NC Munshi, and RO1-50947 to Dr KC Anderson. This research was also supported in part by a kind donation from Mr and Mrs Stewart Nagler. Dr KC Anderson is an American Cancer Society Clinical Research Professor.

REFERENCES

Multiepitope cocktail to treat smoldering myeloma

J Bae et al


Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)